Method and Composition of Less Immunogenic, Long Circulating EPO

Over one million patients in the U.S. are prescribed a therapeutic erythropoietin to treat anemia caused by kidney failure or cancer chemotherapy. It is estimated that over 80% of cancer patients and 87% of patients with severe kidney disease devel op this condition. Treatment is critical considering the high mortality rate associated with the presence of anemia in these patient groups. Currently available therapies suffer from several problems including the production of neutralizing antibod ies, frequent administration, and safety concerns issued by the FDA surrounding overdosing. Pharmaceutical scientists at the University at Buffalo have found a potential means for overcoming these setbacks by encapsulating the protein in a delivery formulation that reduces immunogenicity, decreases the frequency of administration, and which may avoid cardiac muscle-associated toxicity. In addition, as the threat of biogenerics becomes a reality in the U.S and Europe, this formulation has th e potential to extend the product lifecycle and curb generic competition by improving upon the current erythropoietin based therapies.

Categories: Therapeutic and Vaccines

Type of Offer: Licensing



Next Patent »
« More Pharmaceutical Patents
« More Medical Patents

Share on      


CrowdSell Your Patent